Third tiotropium inhaler adds to treatment options for COPD patients

Tiogiva is a new breath-actuated inhaler containing the long-acting anticholinergic tiotropium as powder in capsules for inhalation via the included device.

Patients should be trained how to use the inhaler by their doctor or other healthcare professional. | GLENMARK
Patients should be trained how to use the inhaler by their doctor or other healthcare professional. | GLENMARK

Tiogiva is licensed as a maintenance bronchodilator treatment to relieve symptoms of patients with COPD. The recommended dose is inhalation of the contents of one capsule once daily via the included dry powder inhaler, at the same time each day.

Each Tiogiva capsule contains 18 microgram tiotropium and, in common with Spiriva (via the Handihaler) and Braltus (via the Zonda inhaler), provides a delivered dose of 10 microgram.

To use the inhaler, the patient should load a capsule into the device then push the piercing button to release the medication. When the patient breathes in, the capsule vibrates to confirm the rate of inhalation is sufficient. Visual confirmation of dose delivery is also possible as the capsules are clear.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in